Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Charlène Rivier, Benoite Mery, Elise Rowinski, Sandrine Sotton, Wafa Bouleftour, Laurent Bertoletti, Olivier Tredan & Nicolas Magne. (2022) Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. Expert Opinion on Drug Safety 21:4, pages 453-465.
Read now
Read now
Ahmad Ebrahimi, Joel S Raichlen, Amy Pointon, Christer Gottfridsson, Jiefen Munley, Paul Hockings, James Cartwright, Nicholas Buss, Johannes Wikström, Li-Ming Gan, Andrew Whittaker, Ali Khalil, Richard T George, Pavlo Garkaviy & David Brott. (2020) Drug-induced myocardial dysfunction – recommendations for assessment in clinical and pre-clinical studies. Expert Opinion on Drug Safety 19:3, pages 281-294.
Read now
Read now
Lidia Rita Corsini, Daniele Fanale, Francesco Passiglia, Lorena Incorvaia, Vincenzo Gennusa, Viviana Bazan & Antonio Russo. (2018) Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opinion on Drug Safety 17:12, pages 1197-1209.
Read now
Read now
Milos Dokmanovic, Kathryn E. King, Nishant Mohan, Yukinori Endo & Wen Jin Wu. (2017) Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab. Expert Opinion on Drug Metabolism & Toxicology 13:7, pages 755-766.
Read now
Read now
Gloria Yang-Kolodji, Shannon M. Mumenthaler, Arjun Mehta, Lingyun Ji & Debu Tripathy. (2015) Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance. Biomarkers 20:5, pages 313-322.
Read now
Read now
Mehmet Ali Nahit Şendur, Sercan Aksoy, Hikmet Yorgun, Nuriye Ozdemir, Fatma Meric Yilmaz, Ozan Yazıcı, Cevdet Zungun, Kudret Aytemir, Nurullah Zengin & Kadri Altundag. (2015) Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer. Current Medical Research and Opinion 31:3, pages 547-556.
Read now
Read now
Xiaosong Zhang & Pamela N Munster. (2014) New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opinion on Pharmacotherapy 15:9, pages 1277-1288.
Read now
Read now
Articles from other publishers (64)
Ana Carla Castro-Guijarro, Angel Matias Sanchez & Marina Inés Flamini. (2023) Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer. Cancers 15:17, pages 4374.
Crossref
Crossref
Shahryar Khoshtinat Nikkhoi, Hediyeh Heydarzadeh, Venu Gopal Vandavasi, Ge Yang, Pedro Louro, Marianne Polunas, Hajar Owji & Arash Hatefi. (2023) A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab’s epitope with versatile biochemical, biological, and medical applications. Immunologic Research.
Crossref
Crossref
C. Petit, A. Escande, T. Sarrade, L. Vaugier, Y. Kirova & A. Tallet. (2023) Radiation therapy in the thoracic region: Radio-induced cardiovascular disease, cardiac delineation and sparing, cardiac dose constraints, and cardiac implantable electronic devices. Cancer/Radiothérapie.
Crossref
Crossref
Mengjia Chen, Jianing Xue, Maoling Wang, Junyao Yang & Ting Chen. (2023) Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology. Cancers 15:11, pages 3055.
Crossref
Crossref
Mengnan Zhao, Chen Chen, Chenyu Zhang, Xinyi Xu, Fangyuan Tian, Bin Wu & Ting Xu. (2023) Cardiotoxicity with human epidermal growth factor receptor-2 inhibitors in breast cancer: Disproportionality analysis of the FDA adverse event reporting system. International Journal of Cardiology 375, pages 87-93.
Crossref
Crossref
Yihua Liu, Li Zheng, Xingjuan Cai, Xiaojun Zhang & Yang Ye. (2023) Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. Frontiers in Cardiovascular Medicine 10.
Crossref
Crossref
Bingying Zhou, Xun Shi, Xiaoli Tang, Quanyi Zhao, Le Wang, Fang Yao, Yongfeng Hou, Xianqiang Wang, Wei Feng, Liqing Wang, Xiaogang Sun, Li Wang & Shengshou Hu. (2022) Functional isolation, culture and cryopreservation of adult human primary cardiomyocytes. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Emily I. Holthuis, Gerard T. Vondeling, Josephina G. Kuiper, Vincent Dezentjé, Mats Rosenlund, Jetty A. Overbeek & Carolien H.M. van Deurzen. (2022) Real-world data of HER2-low metastatic breast cancer: A population based cohort study. The Breast 66, pages 278-284.
Crossref
Crossref
Jean C. Bikomeye, Janée D. Terwoord, Janine H. Santos & Andreas M. Beyer. (2022) Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress. American Journal of Physiology-Heart and Circulatory Physiology 323:4, pages H702-H720.
Crossref
Crossref
Ruby Srivastava. (2022) Computational Studies on Antibody Drug Conjugates (ADCs) for Precision Oncology. ChemistrySelect 7:34.
Crossref
Crossref
Humayra Afrin, Md Nurul Huda, Tamanna Islam, Beu P. Oropeza, Efren Alvidrez, Muhammad I. Abir, Thomas Boland, David Turbay & Md Nurunnabi. (2022) Detection of Anticancer Drug-Induced Cardiotoxicity Using VCAM1-Targeted Nanoprobes. ACS Applied Materials & Interfaces 14:33, pages 37566-37576.
Crossref
Crossref
Marco Bruno Morelli, Chiara Bongiovanni, Silvia Da Pra, Carmen Miano, Francesca Sacchi, Mattia Lauriola & Gabriele D’Uva. (2022) Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Md Abdus Subhan & Vladimir P. Torchilin. (2021) Advances with antibody-drug conjugates in breast cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics 169, pages 241-255.
Crossref
Crossref
Susan F. Dent, Amber Morse, Sarah Burnette, Avirup Guha & Heather Moore. (2021) Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Current Oncology Reports 23:11.
Crossref
Crossref
V. I. Potievskaya, A. A. Akhobekov, L. V. Bolotina, L. A. Koroleva & A. D. Kaprin. (2021) CARDIOVASCULAR COMPLICATIONS OF ANTITUMOR THERAPY FOR BREAST CANCER: DIAGNOSIS, PREVENTION AND TREATMENT. Siberian journal of oncology 20:5, pages 138-148.
Crossref
Crossref
Xiao Fu, Juan Tang, Ping Wen, Zezhi Huang & Masoud Najafi. (2021) Redox interactions-induced cardiac toxicity in cancer therapy. Archives of Biochemistry and Biophysics 708, pages 108952.
Crossref
Crossref
Joshua Z. Drago, Shanu Modi & Sarat Chandarlapaty. (2021) Unlocking the potential of antibody–drug conjugates for cancer therapy. Nature Reviews Clinical Oncology 18:6, pages 327-344.
Crossref
Crossref
Meng Xu, Yong Wang & Hua-Cheng Wang. (2021) Adjuvant concomitant treatment with traditional Chinese medicines in patients receiving chemotherapy for HER2-Positive breast cancer: A pilot randomized controlled trial. Complementary Therapies in Clinical Practice 43, pages 101373.
Crossref
Crossref
Katia Khoury, Filipa Lynce, Ana Barac, Xue Geng, Chau Dang, Anthony F. Yu, Karen L. Smith, Christopher Gallagher, Paula R. Pohlmann, Raquel Nunes, Pia Herbolsheimer, Robert Warren, Monvadi B. Srichai, Mark Hofmeyer, Federico Asch, Ming Tan, Claudine Isaacs & Sandra M. Swain. (2021) Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Research and Treatment 185:3, pages 863-868.
Crossref
Crossref
Pierre Loap, Nicolas Tkatchenko, Eliot Nicolas, Alain Fourquet & Youlia Kirova. (2020) Optimization and auto-segmentation of a high risk cardiac zone for heart sparing in breast cancer radiotherapy. Radiotherapy and Oncology 153, pages 146-154.
Crossref
Crossref
Pierre Loap, Krassen Kirov & Youlia Kirova. (2020) Cardiotoxicity in breast cancer patients treated with radiation therapy: From evidences to controversies. Critical Reviews in Oncology/Hematology 156, pages 103121.
Crossref
Crossref
Y. Kirova, A. Tallet, M.C. Aznar, P. Loap, A. Bouali & C. Bourgier. (2020) Radio-induced cardiotoxicity: From physiopathology and risk factors to adaptation of radiotherapy treatment planning and recommended cardiac follow-up. Cancer/Radiothérapie 24:6-7, pages 576-585.
Crossref
Crossref
Sherry-Ann Brown, Jordan C. Ray & Joerg Herrmann. (2020) Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Journal of Cardiovascular Translational Research 13:3, pages 402-416.
Crossref
Crossref
Melissa Y. Y. Moey, Darla K. Liles & Blase A. Carabello. (2019) Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study. Cardio-Oncology 5:1.
Crossref
Crossref
Giuseppe Curigliano, Evandro Azambuja, Daniel Lenihan, Maria Grazia Calabrò, Daniela Cardinale & Carlo Maria Cipolla. (2019) Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. The Oncologist 24:11, pages e1034-e1043.
Crossref
Crossref
Jie An & M. Saeed Sheikh. (2019) Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity. Current Cancer Drug Targets 19:5, pages 400-407.
Crossref
Crossref
Denis Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen & Gerhard Niederfellner. (2019) Acquired Resistance to Antibody-Drug Conjugates. Cancers 11:3, pages 394.
Crossref
Crossref
Loral E. Showalter, Crystal Oechsle, Nirmala Ghimirey, Chase Steele, Brian J. Czerniecki & Gary K. Koski. (2019) Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. PLOS ONE 14:1, pages e0210209.
Crossref
Crossref
Irving E Perez, Sara Taveras Alam, Gabriel A Hernandez & Rhea Sancassani. (2019) Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clinical Medicine Insights: Cardiology 13, pages 117954681986644.
Crossref
Crossref
Angeline Ginzac, Judith Passildas, Emilie Gadéa, Catherine Abrial, Ioana Molnar, Romain Trésorier, Martine Duclos, Emilie Thivat & Xavier Durando. (2019) Treatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical Activity. Oncology 96:5, pages 223-234.
Crossref
Crossref
Ajay Vallakati, Bhavana Konda, Daniel J. Lenihan & Ragavendra R. Baliga. (2018) Management of Cancer Therapeutics–Related Cardiac Dysfunction. Heart Failure Clinics 14:4, pages 553-567.
Crossref
Crossref
Chen Wang, Pan Xu, Luyu Zhang, Jing Huang, Kongkai Zhu & Cheng Luo. (2018) Current Strategies and Applications for Precision Drug Design. Frontiers in Pharmacology 9.
Crossref
Crossref
Nabeel Quryshi, Laura Norwood Toro, Karima Ait-Aissa, Amanda Kong & Andreas Beyer. (2018) Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection—The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. International Journal of Molecular Sciences 19:3, pages 797.
Crossref
Crossref
Kelly C. Gast, Paul V. Viscuse, Somaira Nowsheen, Tufia C. Haddad, Robert W. Mutter, Andrea E. Wahner Hendrickson, Fergus J. Couch & Kathryn J. Ruddy. (2018) Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Current Treatment Options in Cardiovascular Medicine 20:2.
Crossref
Crossref
A. Vallakati, B. Konda & R. Baliga. 2018. Encyclopedia of Cardiovascular Research and Medicine. Encyclopedia of Cardiovascular Research and Medicine
406
416
.
A. Vallakati. 2018. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Giuseppe Fiorentino, Antonio M. Esquinas & Anna Annunziata. 2018. Mechanical Ventilation in Critically Ill Cancer Patients. Mechanical Ventilation in Critically Ill Cancer Patients
123
129
.
Ping-Pin Zheng, Jin Li & Johan M Kros. (2018) Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Medicinal Research Reviews 38:1, pages 325-376.
Crossref
Crossref
Aiko Nagayama, Leif W. Ellisen, Bruce Chabner & Aditya Bardia. (2017) Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Targeted Oncology 12:6, pages 719-739.
Crossref
Crossref
Hye Duck Choi & Min Jung Chang. (2017) Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. Breast Cancer Research and Treatment 166:3, pages 927-936.
Crossref
Crossref
Ji Soo Park, Jong-Chan Youn, Chi Young Shim, Geu-Ru Hong, Choong-Kun Lee, Jee Hyung Kim, Hyung Soon Park, Su Jin Heo, Seung Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung, Seok-Min Kang & Minkyu Jung. (2017) Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Oncotarget 8:37, pages 61837-61845.
Crossref
Crossref
Grace H. Tang, Sergio A. Acuna, Laura Sevick, Andrew T. Yan & Christine Brezden-Masley. (2017) Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single “real-world” setting. Medical Oncology 34:9.
Crossref
Crossref
Prajwal Reddy, Chetan Shenoy & Anne H. Blaes. (2017) Cardio-oncology in the older adult. Journal of Geriatric Oncology 8:4, pages 308-314.
Crossref
Crossref
Maha Rebaї, Imen Kallel, Rania Abdelhedi, Najla kharrat, Nouha Abdemoula Bouayed, Leila Abid & Ahmed Rebaї. (2017) Association analysis of polymorphisms in EGFR , HER2 , ESR1 and THRA genes with coronary artery diseases. Egyptian Journal of Medical Human Genetics 18:3, pages 241-248.
Crossref
Crossref
Benjamin Kenigsberg, Varun Jain & Ana Barac. (2017) Cardio-oncology Related to Heart Failure. Heart Failure Clinics 13:2, pages 297-309.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
243
264
.
Jay Harper & Robert Hollingsworth. 2016. Antibody‐Drug Conjugates. Antibody‐Drug Conjugates
33
58
.
S Schneider, D Thurnher, L Kadletz, R Seemann, M Brunner, U Kotowski, R Schmid, C Lill & G Heiduschka. (2016) Effects of neratinib and combination with irradiation and chemotherapy in head and neck cancer cells. Oral Diseases 22:8, pages 797-804.
Crossref
Crossref
Zarha Vermeulen, Vincent F. M. Segers & Gilles W. De Keulenaer. (2016) ErbB2 signaling at the crossing between heart failure and cancer. Basic Research in Cardiology 111:6.
Crossref
Crossref
Brian Z. Huang & Melissa S. Camp. (2016) Burden of preoperative cardiovascular disease risk factors on breast cancer surgery outcomes. Journal of Surgical Oncology 114:2, pages 144-149.
Crossref
Crossref
Noelia Martínez-Jañez, Ignacio Chacón, Ana de Juan, Luis Cruz-Merino, Sònia del Barco, Isaura Fernández, Paula García-Teijido, Amalia Gómez-Bernal, Arrate Plazaola, José Ponce, Sonia Servitja & Pilar Zamora. (2016) Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel. Breast Care 11:2, pages 133-138.
Crossref
Crossref
Ufuk Eryilmaz, Buket Demirci, Saliha Aksun, Murat Boyacioglu, Cagdas Akgullu, Tevfik Fikret Ilgenli, Hande Sultan Yalinkilinc & Mehmet Bilgen. (2015) S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers. PLOS ONE 10:12, pages e0145418.
Crossref
Crossref
Alessio Di Luca, Michael Henry, Paula Meleady & Robert O’Connor. (2015) Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment. DARU Journal of Pharmaceutical Sciences 23:1.
Crossref
Crossref
Jasmeet Chadha Singh & Stuart M. Lichtman. (2015) Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs & Aging 32:12, pages 975-982.
Crossref
Crossref
Lu Yang, Yun Li, Arup Bhattacharya & Yuesheng Zhang. (2015) Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine 2:5, pages 396-405.
Crossref
Crossref
Paola Rizzo, Donato Mele, Cristiana Caliceti, Micaela Pannella, Cinzia Fortini, Anthony George Clementz, Marco Bruno Morelli, Giorgio Aquila, Pietro Ameri & Roberto Ferrari. (2015) The Role of Notch in the Cardiovascular System: Potential Adverse Effects of Investigational Notch Inhibitors. Frontiers in Oncology 4.
Crossref
Crossref
Mehmet AN Sendur, Sercan Aksoy & Kadri Altundag. (2015) Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab. Future Oncology 11:1, pages 13-15.
Crossref
Crossref
Eric R. Schuur & James P. DeAndrade. 2015. International Manual of Oncology Practice. International Manual of Oncology Practice
155
200
.
Guilherme H. OliveiraMarwan Y. QattanSadeer Al-KindiSoon J. Park. (2014) Advanced Heart Failure Therapies for Patients With Chemotherapy-Induced Cardiomyopathy. Circulation: Heart Failure 7:6, pages 1050-1058.
Crossref
Crossref
Margrét Bessadóttir, Edda Á. Skúladóttir, Sharon Gowan, Suzanne Eccles, Sesselja Ómarsdóttir & Helga M. Ögmundsdóttir. (2014) Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells. Phytomedicine 21:12, pages 1717-1724.
Crossref
Crossref
Ciara C. O’Sullivan & Karen L. Smith. (2014) Therapeutic Considerations When Treating HER2-positive Metastatic Breast Cancer. Current Breast Cancer Reports 6:3, pages 169-182.
Crossref
Crossref
John M. Lambert & Ravi V. J. Chari. (2014) Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer. Journal of Medicinal Chemistry 57:16, pages 6949-6964.
Crossref
Crossref
Adedayo A. Onitilo, Jessica M. Engel & Rachel V. Stankowski. (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Therapeutic Advances in Drug Safety 5:4, pages 154-166.
Crossref
Crossref
Ditte Brix, Knut Clemmensen & Tuula Kallunki. (2014) When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase. Cells 3:1, pages 53-78.
Crossref
Crossref